SARS-CoV-2-IN-27
PRODUCTS SPECIFICATIONS
DESCRIPTION
Overview
| MDL | - |
|---|---|
| Molecular Weight | 894.97 |
| Molecular Formula | C54H56O8P2 |
| SMILES | OP(OC1=C2C(C3C4=C(C2C3)C=C5C(C6C7=C(C5C6)C=CC=C7)=C4)=C(C8=C1C9C%10=CC(C%11CC%12C%13=C%11C=CC=C%13)=C%12C=C%10C8C9)OP(OCCCCCC)(O)=O)(OCCCCCC)=O |
Summary
SARS-CoV-2-IN-27 is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 exhibits antiviral activity with IC 50 s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 induces liposomal membrane disruption with an EC 50 value of 6.5 μM [1] .
IC50 & Target
IC50: 6.5 μM (viral liposome, SARS-CoV-2) [1]
In Vitro
SARS-CoV-2-IN-27 (CP019) inhibits SARS-CoV-2 (IC
50
=1.7 μM) with few cytotoxicity (Caco2 cells, CC
50
=208 μM)
[1]
.
SARS-CoV-2-IN-27 (0-15 μM; 2 h) inactivate SARS-CoV-2, shows inhibition against infection with an IC
50
value of 1.0 μM
[1]
.
SARS-CoV-2-IN-27 suppresses varies enveloped viruses activity with IC
50
s of 7.4 μM (respiratory syncytial virus, RSV), 112.6 μM (influenza A virus, IAV), 4.6 μM (measles virus, MeV), 1.8 μM (herpes simplex viruses, HSV-1), respectively
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | Caco2 cells exposed with SARS-CoV-2 (2 h, 37 ℃) |
| Concentration: | 0, 0.23, 0.93, 3.75, 15 μM |
| Incubation Time: | 2 hours; determined infection rates on day 2 |
| Result: | Inhibited SARS-CoV-2 infection activity to Caco2 cells. |
In Vivo
SARS-CoV-2-IN-27 (CP019) (150 μM, 50 μL; intranasal route; for 2-5 d) shows antiviral activity in vivo against respiratory syncytial virus (RSV) and SARS-CoV-2 in BALB/cJ mice or K18-hACE2 mice, respectively
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Respiratory syncytial virus (RSV) infection of BALB/cJ mice and SARS-CoV-2 infection of K18-hACE2 mice [1] |
| Dosage: | 150 μM, 50 μL |
| Administration: | Intranasal route; single dose; sacrificed BALB/cJ mice on day 5; treated K18-hACE2 mice once again after 7 h and sacrificed mice on day 2 |
| Result: |
Reduced viral load in the lungs of SARS-CoV-2-infected mice.
Completely abolished SARS-CoV-2 infection of all tested mice without changing body weight of mice. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.